Could CD47 Competitors Catch Up To Gilead After Magrolimab Hold?
Executive Summary
Gilead isn’t giving details about the events behind the partial hold on magrolimab/Vidaza combination studies, but analysts suspect cytopenias are the culprit.
You may also be interested in...
Things Get Worse For Gilead’s Magrolimab
Gilead said the FDA requested a partial clinical hold on the studies as well, just over a week after the drug maker said it would not develop the magrolimab further for blood cancers.
Gilead’s Magrolimab Hit With Third Clinical Hold, This Time In AML
Gilead’s novel immune checkpoint inhibitor candidate, magrolimab, has been placed on a partial clinical hold by the US Food and Drug Administration in acute myeloid leukemia, adding to a spate of recent setbacks for the therapy that are chipping away at investor confidence.
Gilead’s Phase III Trial Halt Raises Questions About Magrolimab’s Value
While the myelodysplastic syndrome trial news seems unlikely to read through to other programs, MDS may have been the drug’s biggest market.